Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Rohto Pharmaceutical Co ( (JP:4527) ) is now available.
Rohto Pharmaceutical Co. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a 14% increase in net sales to ¥308,625 million. Despite the rise in sales, the company experienced a decline in operating and ordinary income by 2.8% and 4.7% respectively, attributed to various market challenges. The company also announced an increase in annual dividends, reflecting a commitment to shareholder returns. The financial results indicate a strategic focus on expanding its market presence and enhancing corporate value through acquisitions, as evidenced by the inclusion of 46 new subsidiaries.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen4770.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry. It is known for its production of health and wellness products, including over-the-counter medications, skincare, and other consumer healthcare products.
Average Trading Volume: 1,357,607
Technical Sentiment Signal: Hold
Current Market Cap: Yen570.9B
Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.